Valneva SE announced final Phase 1 study data and positive initial booster data for its Lyme Disease vaccine candidate VLA15.
“The positive final Phase 1 data for VLA15 supports and validates our plans to continue developing a safe and effective preventative vaccine that can be delivered to those who are at risk of Lyme disease infection,” said Thomas Lingelbach, CEO of Valneva.
“We look forward to continuing the development process with our recently initiated Phase 2 study. We continue to fully commit ourselves to addressing the significant unmet need for a vaccine against Lyme disease.”
Read more
Comments are closed.